Currently Biotest markets 14 different products in three therapeutic areas: clinical immunology, haematology and intensive care medicine. Further products are currently under development for other indications.
All Biotest products are biological drugs that are either obtained directly from human plasma or manufactured using biological methods. The products from Biotest are used to treat patients with severe and often life-threatening diseases of the blood and the immune system.
We aim to develop new products for the treatment or management of diseases for which there is no current effective treatment, or where existing treatments are associated with substantial side effects.
The highest possible level of safety and quality from blood plasma donation to patient treatment is absolutely crucial. We work constantly to further improve our already strict standards over and above those required by the regulatory authorities. The depth of experience of the employees at Biotest plays a key role in ensuring success in this approach.